Aclaris Therapeutics, Inc.
ACRSNasdaq
$5.68
↑ +6.0%Jul 17 close · end-of-day
Price
1Y↑ +259.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$731.6M
Enterprise Value
$626.2M
P/E
—
P/S
87.4
P/B
5.1
EV/EBITDA
—
PEG
—
FCF Yield
-7.1%
Dividend Yield
—
Revenue (TTM)
$8.4M
Net Income (TTM)
-$69.7M
Free Cash Flow (TTM)
-$52.3M
Gross Margin
—
Operating Margin
-961.9%
Net Margin
-832.6%
ROE
-48.5%
ROIC
-166.3%
Debt / Equity
—
Net Cash
$105.4M
Return 1Y
+257.2%
Company profile
Aclaris Therapeutics, Inc. develops novel drug candidates for immune-inflammatory diseases in the United States. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa.
- CEO
- Neal S. Walker
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- Pennsylvania
- Website
- aclaristx.com
Management & directors
- Hall Jesse WayneChief Medical Officer
- Balthaser KevinChief Financial Officer
- Davis Hugh M.President and COO
- Loerop JamesChief Business Officer
- Walker NealCEO
Roles derived from SEC Form 4 filings.
Earnings
ACRS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.0M↑ +37.2%
Diluted EPS-$0.15↑ +25.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.5M | $6.8M | $29.8M | $31.2M | $18.7M | $7.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$50.9M | -$89.7M | -$89.9M | -$97.4M | -$141.9M | -$76.4M |
| Net income | -$51.0M | -$90.9M | -$86.9M | -$88.5M | -$132.1M | -$64.9M |
| Diluted EPS | -$1.20 | -$1.60 | -$1.33 | -$1.27 | -$1.71 | -$0.53 |
| Operating cash flow | -$38.6M | -$52.1M | -$67.6M | -$78.3M | -$20.1M | -$47.1M |
| Free cash flow | -$39.1M | -$52.4M | -$68.2M | -$79.6M | -$20.2M | -$47.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -785.4% | -1327.1% | -302.0% | -311.6% | -758.2% | -975.9% |
| Net margin | -787.0% | -1344.0% | -292.1% | -283.1% | -705.5% | -829.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $4.3M | $9.2M | $1.5M | $1.8M | $3.3M | $1.3M | $2.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$12.9M | -$10.5M | -$99.7M | -$18.1M | -$18.4M | -$17.1M | -$22.7M | -$22.2M |
| Net income | -$11.0M | -$7.6M | -$96.6M | -$15.1M | -$15.4M | -$14.6M | -$19.8M | -$19.8M |
| Diluted EPS | -$0.15 | -$0.11 | -$1.21 | -$0.12 | -$0.13 | -$0.12 | -$0.16 | -$0.15 |
| Operating cash flow | -$12.3M | $22.0M | -$8.9M | -$13.1M | -$10.0M | -$10.9M | -$13.1M | -$18.1M |
| Free cash flow | -$12.3M | $22.0M | -$8.9M | -$13.1M | -$10.0M | -$11.0M | -$13.2M | -$18.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -464.7% | -240.9% | -1082.3% | -1242.9% | -1035.9% | -519.8% | -1755.5% | -1111.8% |
| Net margin | -397.2% | -174.6% | -1048.3% | -1036.8% | -868.3% | -443.0% | -1528.6% | -993.2% |
Company news
Jul 1, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-05 | Mehra Anand | Option exercise | 11,580 | — | — | filing |
| 2026-06-05 | SCHIFF ANDREW N | Option exercise | 11,580 | — | — | filing |
| 2026-06-05 | Humphries William D. | Option exercise | 11,580 | — | — | filing |
| 2026-06-05 | Molineaux Christopher P. | Option exercise | 11,580 | — | — | filing |
| 2026-06-05 | MILANO VINCENT | Option exercise | 11,580 | — | — | filing |
| 2026-06-05 | GOWEN MAXINE | Option exercise | 11,580 | — | — | filing |
| 2026-05-01 | Hall Jesse Wayne· Chief Medical Officer | Tax withholding | 9,330 | $4.41 | $41,145.30 | filing |
| 2026-05-01 | Hall Jesse Wayne· Chief Medical Officer | Option exercise | 36,375 | — | — | filing |
| 2026-04-23 | Leonard Braden Michael | Sale | 300,000 | $4.53 | $1.4M | filing |
| 2026-03-01 | Balthaser Kevin· Chief Financial Officer | Tax withholding | 677 | $2.87 | $1,942.99 | filing |
| 2026-03-01 | Balthaser Kevin· Chief Financial Officer | Option exercise | 2,375 | — | — | filing |
| 2026-02-03 | Walker Neal· CEO | Tax withholding | 18,611 | $3.47 | $64,580.17 | filing |
| 2026-02-03 | Balthaser Kevin· Chief Financial Officer | Tax withholding | 6,449 | $3.47 | $22,378.03 | filing |
| 2026-02-03 | Loerop James· Chief Business Officer | Tax withholding | 5,937 | $3.47 | $20,601.39 | filing |
| 2026-02-03 | Davis Hugh M.· President and COO | Option exercise | 18,675 | — | — | filing |
| 2026-02-03 | Loerop James· Chief Business Officer | Option exercise | 20,875 | — | — | filing |
| 2026-02-03 | Walker Neal· CEO | Option exercise | 63,475 | — | — | filing |
| 2026-02-03 | Balthaser Kevin· Chief Financial Officer | Option exercise | 22,025 | — | — | filing |
| 2026-02-01 | Loerop James· Chief Business Officer | Tax withholding | 10,686 | $3.51 | $37,507.86 | filing |
| 2026-02-01 | Balthaser Kevin· Chief Financial Officer | Tax withholding | 4,984 | $3.51 | $17,493.84 | filing |
| 2026-02-01 | Loerop James· Chief Business Officer | Option exercise | 11,250 | — | — | filing |
| 2026-02-01 | Loerop James· Chief Business Officer | Option exercise | 7,500 | — | — | filing |
| 2026-02-01 | Loerop James· Chief Business Officer | Option exercise | 14,750 | — | — | filing |
| 2026-02-01 | Balthaser Kevin· Chief Financial Officer | Option exercise | 14,750 | — | — | filing |
| 2026-01-02 | Walker Neal· CEO | Tax withholding | 9,952 | $2.88 | $28,661.76 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.